Phosphoenolpyruvate Restricts cGAS-STING Inflammation in Aging

Study Background and Research Question

Aging is universally characterized by a progressive decline in organ function and a rise in chronic disease risk. One key feature of aging, termed 'inflammaging', involves low-grade, persistent inflammation that disrupts homeostasis and accelerates tissue degeneration. Central to this process is the cGAS–STING signaling pathway, which is activated by cytoplasmic DNA fragments accumulating during cellular senescence and damage. Chronic activation of cGAS–STING drives pro-inflammatory signaling, contributing to neurodegeneration, cardiovascular dysfunction, and systemic frailty. Despite recognition of these pathways, little is known about the endogenous metabolic adaptations that may restrain age-related inflammation. The current study sought to identify intrinsic metabolites capable of modulating cGAS–STING activity during aging and to elucidate their mechanistic roles in inflammation control.

Key Innovation from the Reference Study

The reference study (Song et al., 2026) uncovers a previously unrecognized function for the glycolytic intermediate phosphoenolpyruvate (PEP) as a direct, endogenous inhibitor of the cGAS–STING pathway. Rather than serving solely as a metabolic substrate, PEP was shown to accumulate transiently in the systemic milieu of aging mice and humans, where it acts as a geroprotective factor. Mechanistically, PEP binds competitively to cGAS, thereby limiting its activation and downstream inflammatory signaling. This self-protective metabolic adaptation delays the onset of chronic inflammation, preserves tissue function, and is associated with healthier aging trajectories.

Methods and Experimental Design Insights

The researchers employed longitudinal metabolomic profiling in both mice and humans to track systemic PEP levels across the lifespan. They observed a biphasic trajectory: an initial accumulation of PEP during the early stages of aging, followed by a significant decline in more advanced age. To probe causality, genetic and pharmacological interventions were used to block PEP accumulation, which resulted in heightened cGAS–STING activation, increased inflammatory mediators, and accelerated aging phenotypes. Conversely, preadministration of PEP before its endogenous decline mitigated inflammation and improved healthspan metrics in mice.

In a series of in vitro and in vivo assays, the team demonstrated that PEP directly interacts with cGAS, inhibiting its enzymatic activity and downstream interferon signaling. Additional experiments in a mouse model of Alzheimer's disease revealed that PEP supplementation reduced neuroinflammation and improved cognitive performance, supporting the broader relevance of PEP's anti-inflammatory action in age-related neurological disorders.

Protocol Parameters

• Metabolite supplementation: Preadministration of PEP prior to its natural decline in aging models, with timing and dosage tailored for the specific phenotype under investigation.
• Inflammation assays: Quantification of systemic and tissue-specific cytokines, assessment of cGAS–STING activation status by immunoblot and qPCR, and measurement of downstream interferon responses.
• Cognitive function tests: Behavioral assays in Alzheimer's mouse models following PEP supplementation to assess memory and learning outcomes.
• Plasma transfer experiments: Transfer of aged or PEP-manipulated plasma to recipient mice to evaluate cell-nonautonomous effects on inflammation.

Core Findings and Why They Matter

Key findings from the study include:

• PEP accumulates transiently in the systemic milieu during early aging but declines as aging progresses.
• High PEP levels correlate with reduced systemic inflammation and healthier aging phenotypes in both mice and humans.
• Preadministration of PEP before its decline ameliorates inflammation, delays aging phenotypes, and improves cognitive outcomes in models of neurodegeneration.
• Mechanistically, PEP acts as an endogenous inhibitor of the cGAS–STING pathway by directly binding to cGAS, thereby reducing the generation of pro-inflammatory mediators.

These results establish PEP not only as a marker but as an active modulator of age-associated inflammation, advancing our understanding of metabolic regulation in healthy aging. By highlighting the cGAS–STING pathway as a modifiable target, this work opens new avenues for interventions aimed at mitigating inflammaging and its associated pathologies.

Comparison with Existing Internal Articles

Several internal resources elaborate on the broader class of glycolytic intermediates, such as hexose diphosphate and hexose phosphate, in metabolic and inflammation research. For example, "Hexose Diphosphate in Metabolic and Inflammation Research" discusses the utility of hexose diphosphate as a versatile probe for dissecting energy metabolism and inflammatory signaling in cardiovascular and aging models. While the reference study focuses on PEP's direct action on cGAS, the internal article emphasizes the use of water-soluble hexose phosphates for metabolic flux analysis and as inflammatory signaling modulators in advanced assays.

Similarly, "Hexose Diphosphate in Energy Homeostasis and Inflammation Models" provides practical protocols for leveraging hexose diphosphate in dissecting metabolic-immune crosstalk. These resources align with the reference study's central theme—that metabolites traditionally viewed as energy carriers can exert regulatory control over inflammation and tissue homeostasis. However, the reference paper is distinctive in elucidating a precise molecular mechanism (cGAS inhibition by PEP), whereas the internal articles primarily focus on workflow implementation and protocol optimization using hexose phosphates.

Limitations and Transferability

Despite the robust evidence, several caveats remain. First, the biphasic pattern of PEP accumulation and decline was established in both mice and humans, but the molecular determinants of this trajectory are not fully resolved. The study's pharmacological interventions were optimized for preclinical models and may not translate directly to human therapeutic regimens without further validation. Additionally, while PEP demonstrated efficacy in an Alzheimer's disease mouse model, its relevance to other neurodegenerative or systemic diseases requires additional exploration. Finally, the specificity of PEP's inhibitory action on cGAS, versus other innate immune sensors or metabolic enzymes, awaits deeper mechanistic investigation.

Transferability to other metabolic intermediates—such as hexose diphosphate—should be pursued cautiously. While the reference study highlights a direct protein-metabolite interaction, the regulatory effects of related glycolytic compounds on innate immune pathways may differ. Nonetheless, the findings underscore the value of integrating metabolic and immunological assays in energy homeostasis research and in the development of novel geroprotective strategies.

Research Support Resources

For researchers aiming to model metabolic–immune interactions or to interrogate the enzymatic regulation of carbohydrate metabolism in vitro, standardized reagents such as hexose diphosphate (SKU M1436) from APExBIO offer practical advantages. This compound is well characterized for its role as a metabolic flux probe and for its solubility in aqueous systems, supporting high-sensitivity analysis in both metabolic and inflammation assays, as described in recent internal reviews. Hexose diphosphate provides a reliable tool to probe energy homeostasis, inflammatory signaling modulation, and the interplay between metabolic and immune pathways in drug discovery and mechanistic research workflows.